Cytosorbents (CTSO) Operating Income Growth (3y) (2014 - 2026)
Cytosorbents (CTSO) Operating Income Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 7.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 75.54% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 34.83% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.70% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytosorbents | 22.58 Mn | 17.78 Mn | 6.13 Mn | 27.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.21% |
| Dec 31, 2025 | 11.64% |
| Sep 30, 2025 | 31.79% |
| Jun 30, 2025 | 24.37% |
| Mar 31, 2025 | 20.68% |
| Dec 31, 2024 | 29.19% |
| Sep 30, 2024 | 3.69% |
| Jun 30, 2024 | 10.17% |
| Mar 31, 2024 | -17.75% |
| Dec 31, 2023 | -52.86% |
| Sep 30, 2023 | -55.37% |
| Jun 30, 2023 | -25.76% |
| Mar 31, 2023 | -47.11% |
| Dec 31, 2022 | -5.38% |
| Sep 30, 2022 | -17.02% |
| Jun 30, 2022 | -32.04% |
| Mar 31, 2022 | -22.05% |
| Dec 31, 2021 | -19.63% |
| Sep 30, 2021 | -25.87% |
| Jun 30, 2021 | -5.55% |